China
Africa
Explore chapters and articles related to this topic
Minimally Invasive Tricuspid Valve Surgery
Published in Theo Kofidis, Minimally Invasive Cardiac Surgery, 2021
Christos Alexiou, Theo Kofidis
Most commonly, TS results from rheumatic heart disease. Other less common causes of TS include congenital abnormalities (Ebstein’s anomaly or isolated tricuspid valve stenosis), metabolic or enzymatic abnormalities (Fabry’s disease, Whipple’s disease and carcinoid) and active infective endocarditis [12]. The 2014 AHA/ACC and ESC Valvular Heart Disease Guidelines recommend tricuspid valve surgery for (a) patients with severe TS at the time of operation for left-sided valve disease and (b) isolated, symptomatic severe TS (Class I recommendations). The guidelines further suggest percutaneous balloon commissurotomy in patients with isolated, symptomatic severe TS without accompanying TR and without calcified tricuspid valve [6–8].
Valvular Heart Disease
Published in P. Chopra, R. Ray, A. Saxena, Illustrated Textbook of Cardiovascular Pathology, 2013
Tricuspid valve stenosis RHD is the most common cause of acquired tricuspid valve stenosis which is associated with involvement of other heart valves (Fig. 4.28). Rarely it may occur consequent to infective endocarditis, carcinoid syndrome or exist as a congenital anomaly
Stroke risk stratification in atrial fibrillation: a review of common risk factors
Published in Journal of Community Hospital Internal Medicine Perspectives, 2019
Oreoluwa Oladiran, Ifeanyi Nwosu
EHRA Type 2 patients are those with AF and VHD requiring therapy with either VKA or NOACs based on CHA2DS2-VASc risk levels. The VHD considered in this category includes mitral regurgitation, mitral valvular repair, aortic stenosis and regurgitation, bioprosthetic valves, pulmonary valve stenosis and regurgitation, tricuspid valve stenosis and regurgitation, and a trans-aortic valve intervention. However, it is important to note that while patients with bioprosthetic valves were excluded from the NOAC trials namely ROCKET-AF [35], RE-LY [36] and ARISTOTLE [37], their use is considered acceptable. Although bioprosthetic valves are known to be less thrombogenic, further research is required to determine long term safety of NOACs in patients with bioprosthetic valves requiring anticoagulation.